ArticleKidney international reports2026
Steroid-Resistant Idiopathic Nephrotic Syndrome Reveals a Distinct Maladaptive Molecular State.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic Insights into the Maladaptive Biology of Steroid-Resistant Nephrotic Syndrome.Kidney international reports · 2026Article
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Idiopathic nephrotic syndrome (iNS) is clinically classified by treatment response; however, the molecular basis of multidrug resistance remains poorly defined. We hypothesized that multidrug-resistant disease represents a distinct biological state rather than a more severe form of active disease. Methods: Serum proteomic profiling using liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed in 165 pediatric and young adult patients with iNS, stratified as steroid-dependent nephrotic syndrome (SDNS), multidrug-dependent nephrotic syndrome (MDNS), or multidrug-resistant nephrotic syndrome (MRNS), and compared with healthy donors. Differential expression, pathway enrichment, and multivariate modeling were used to identify discriminative proteins. Selected biomarkers were validated using enzyme-linked immunosorbent assay (ELISA) and independently replicated in a separate validation cohort. Functional effects of patient-derived sera were assessed in cultured human podocytes and peripheral blood mononuclear cells (PBMCs). Results: Of 810 quantified proteins, 322 differed significantly across clinical groups. A 35-protein signature discriminated MRNS from MDNS and SDNS phenotypes. Integrated analyses identified dystroglycan 1 (DAG1), CD44 antigen (CD44), and RISC-loading complex subunit (TARBP2) as principal contributors to phenotype separation. ELISA confirmed increased DAG1 in MRNS, preserved TARBP2 in remission, and increased CD44 in active disease. Sera from patients with MRNS induced coordinated alterations in cytoskeletal organization, proteostasis, autophagy, and survival signaling in podocytes. An inverse distribution of endoplasmic reticulum (ER) chaperone BIP (GRP78) and phosphorylated AKT (pAKT) was observed in both serum-treated podocytes and patient PBMCs. Conclusion: MRNS is associated with a distinct proteomic and functional profile characterized by coordinated stress-response dysregulation, supporting biologically informed disease stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.